



Financial Tear Sheet

Corporate Profile

Paratek is developing and commercializing innovative antibacterial therapeutics based upon tetracycline chemistry. Paratek has used its expertise in microbial biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the tetracycline class of molecules. Paratek’s two lead antibacterial product candidates are omadacycline and sarecycline. Omadacycline entered Phase 3 clinical development in June 2015. Sarecycline entered Phase 3 clinical development in December 2014.

Stock Information

PRTK (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$13.98
Change (%)	▲ 0.03 (0.22%)
Volume	424,128
52 Week Low	\$11.85
Market Cap	\$434,582,923
Rolling EPS	-3.66
PE Ratio	N/A
Shares Outstanding	31,097,168

Data as of 02/16/18 4:00 p.m. ET



Recent Paratek Pharmaceuticals News & Events

	Date	Title
02/15/18 - 8:01 a.m. Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results on March 1, 2018		
02/05/18 - 7:30 a.m. Paratek Completes Submission of New Drug Applications to U.S. Food and Drug Administration for Oral and Intravenous Omadacycline for Pneumonia and Skin Infections		
02/01/18 - 4:03 p.m. Paratek Announces Inducement Grants	03/01/18 8:30 a.m. ET	Q4 2017 Paratek Pharmaceuticals Inc Earnings Conference Call

SEC Filings

Filing Date	Form
-------------	------

02/16/18	4
----------	---

02/16/18	4
----------	---

02/16/18	4
----------	---

02/16/18	4
----------	---

Management

Randy Brenner	Senior Vice President - Regulatory, Quality and Technical Operations
---------------	--

Jason Burdette	Vice President - Technical Operations
----------------	--

Jeanne Jew	Senior Vice President - Business Development
------------	---

Raj Padmanabhan	Vice President - Information Technology
-----------------	--

Regina Paglia	Senior Vice President - Human Resources
---------------	--

Susan Perkins, J.D.	Vice President - Intellectual Property
------------------------	---

Evan Tzanis	Senior Vice President - Clinical Development & Clinical Operations
-------------	--

Michael F. Bigham	Chief Executive Officer and Chairman of the Board
-------------------	---

Evan Loh, M.D. President, Chief
Operating Officer and
Chief Medical Officer

William Haskel General Counsel and
Corporate Secretary

Douglas W. Pagán Chief Financial Officer

Adam Woodrow Chief Commercial Officer

Data provided by Nasdaq. Minimum 15 minutes delayed.